Capmatinib (Capatinib) Detailed Drug Purchasing and Medication Manual

Capatinib, whose trade name isTabrecta, is a targeted therapy drug designed to treat patients with specific types of non-small cell lung cancer (NSCLC), especially those with advanced NSCLC who carry MET gene exon 14 skipping mutations. The following is a detailed guide on purchasing and taking capmatinib.

1. Drug Purchase Manual

When purchasing capmatinib, it is important to choose formal channels. Patients can consider the following ways to purchase medicines:

1. Assistance from relatives and friends: If the patient has overseas relatives and friends, he or she can ask them to help with the purchase, and pay attention to complying with relevant customs and transportation regulations.

2. Professional institutions: Some professional medical service institutions have cooperative relationships with overseas pharmacies or pharmaceutical factories and can assist patients in obtaining drugs and provide corresponding protection.

When purchasing drugs, patients should carefully check the version, strength, and manufacturer of the drug, as the prices of different versions and strengths of drugs may vary significantly. For example, the price of the Hong Kong version of the original drug may be as high as 30,000 to 40,000 yuan per box, while the price of generic drugs in Laos may be more affordable, about 3,000 to 4,000 yuan. At the same time, patients should also check the shelf life of medicines to ensure that they are purchasing qualified and effective products.

2. Medication Manual

When using capmatinib, patients should strictly follow their doctor's instructions. The recommended dosage is 400 mg twice daily (usually two 200 mg tablets), which can be taken before or after meals. Patients should keep the tablets intact while taking the medication and avoid breaking, crushing or chewing it.

During the medication process, patients should pay close attention to their body reactions, especially any possible adverse reactions, such as swelling of hands or feet, nausea, fatigue, vomiting, loss of appetite, etc. Once these symptoms occur, you should report it to your doctor promptly. Especially when patients experience serious adverse reactions such as interstitial lung disease (ILD)/pneumonitis and liver toxicity, they should stop taking the medication immediately and seek medical treatment.

In addition, because capmatinib has the potential risk of photosensitivity reaction, patients should take corresponding preventive measures during treatment, such as avoiding prolonged exposure to the sun, using sunscreen or wearing protective clothing. Pregnant and lactating women should fully understand the potential risks and seek medical advice before using capmatinib.

Overall, capmatinib, as an effective targeted therapy, provides a new treatment option for patients with specific types of non-small cell lung cancer. When purchasing and using, patients should make sure to choose formal channels and strictly follow the doctor's instructions to ensure the safety and efficacy of the medication.